ASLAN Pharmaceuticals Limited (ASLN) News
Filter ASLN News Items
ASLN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ASLN News Highlights
- For ASLN, its 30 day story count is now at 2.
- Over the past 22 days, the trend for ASLN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- AA, DX and NOV are the most mentioned tickers in articles about ASLN.
Latest ASLN News From Around the Web
Below are the latest news stories about ASLAN PHARMACEUTICALS LTD that investors may wish to consider to help them evaluate ASLN as an investment opportunity.
ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat ProgramsFollowing the successful TREK-AD Phase 2b study of eblasakimab in moderate-to-severe atopic dermatitis, process is underway to identify potential partners. Recruitment in TREK-DX, studying eblasakimab in dupilumab-experienced patients, using updated criteria based on findings from TREK-AD, has commenced at US sites, with additional sites in Europe expected to open in the first half of 2024.Review of blinded safety data emerging from FAST-AA study of farudodstat in alopecia areata shows no emergi |
ASLAN Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare ConferenceSAN MATEO, Calif. and SINGAPORE, Nov. 20, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, will participate in a fireside discussion at the Piper Sandler Healthcare Conference. The conference will be held from November 28 to 30, 2023, in-person at the Lotte New York Palace Hotel, in New York. 35TH Annual Piper Sandler |
ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development SummitHead-to-head study between eblasakimab and dupilumab in skin biopsies from atopic dermatitis (AD) patients confirm eblasakimab’s differentiated effects of targeting IL-13R vs IL-4RUsing an established COPD model of human lung slices, new data demonstrate eblasakimab’s potential to reduce airway constriction and enhance dilationResults demonstrate for the first time the potential utility of eblasakimab in other indications beyond AD SAN MATEO, Calif. and SINGAPORE, Nov. 03, 2023 (GLOBE NEWSWIRE) |
ASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatePositive topline data reported in July from TREK-AD, a Phase 2b study of eblasakimab in moderate-to-severe atopic dermatitis, met the primary endpoint across three dosing arms; the study established eblasakimab’s potential to deliver a monthly dosing regimen from initiation with a competitive efficacy profile. Preparations underway for the advancement of eblasakimab into Phase 3 clinical development in 2024.Topline interim data from the FAST-AA (FArudodstat STudy in Alopecia Areata) Phase 2a stu |
ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion Today on Changes in the Clinical Trial and Treatment Landscape for Atopic DermatitisDiscussion featuring KOLs Dr Jonathan Silverberg, Dr April W. Armstrong, and a leading CRO will explore “The Changing Face of Atopic Dermatitis: How the Clinical Trial and Treatment Landscape Has Changed in the Seven Years Following Dupilumab’s Introduction”ASLAN management will present additional analyses from the TREK-AD study and new market research from prescriber and patient surveys on the AD treatment landscape Register here to attend the webcast event today at 11:00am ET SAN MATEO, Calif. |
ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic DermatitisASLAN management will present emerging data from the TREK-AD study and new market research data on the AD treatment landscape from patient and prescriber surveysRegister here to attend the webinar event on October 24, 2023 at 11:00 am ET SAN MATEO, Calif. and SINGAPORE, Oct. 18, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it w |
ASLAN Pharmaceuticals Presents New Data From Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker Presentation at 32nd European Academy of Dermatology and Venereology CongressData presented during the late-breaker oral presentation of the TREK-AD study demonstrate eblasakimab’s potential as the first biologic in moderate-to-severe atopic dermatitis to demonstrate a competitive efficacy profile with once-monthly dosing from initiation New data from a post-hoc analysis of patients with severe disease (baseline EASI score at least 21), representing 63% of ITT patients, show monthly dosing with 600 mg eblasakimab for 16 weeks led to a 74.5% reduction in EASI score (versu |
3 Stocks to Sell Ahead of the Coming VIX SpikeAs the VIX's cycle begins to creep upward, investors would be wise to bail on these stocks to sell before their volatility destroys returns. |
ASLAN Pharmaceuticals Announces Acceptance of Late Breaker Abstract on Eblasakimab Phase 2b Results as Oral Presentation and Three Additional Abstracts at 32nd European Academy of Dermatology and Venereology CongressSAN MATEO, Calif. and SINGAPORE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that four abstracts on eblasakimab and farudodstat have been accepted for e-poster and oral presentations at the 32nd European Academy of Dermatology and Venereology (EADV), taking place from October 11 to 14, 2023, in Berlin, Germany, at the Mes |
ASLAN Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceSAN MATEO, Calif. and SINGAPORE, Sept. 07, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that management will give an in-person company presentation at the H.C. Wainwright 25th Annual Global Investment Conference, to be held both virtually and in-person at the Lotte New York Palace Hotel in New York City, from September 11 to 13, 202 |